Loading company
Context Therapeutics Inc.
CNTX · Nasdaq · ·
Next earnings: November 4, 2026
$0.32-2.2%Sep 29 close
- 1M
- -17.1%
- 6M
- -87.0%
- 1Y
- -67.2%
CNTX · Nasdaq · ·
Next earnings: November 4, 2026
$0.32-2.2%Sep 29 close
Context Therapeutics Inc. is scheduled to report next on November 4, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Profit | -$14.6M | -$8.8M | -64.92% |
| Profit per share | -$0.15 | -$0.09 | -66.67% |
| Free Cash Flow | -$7M | -$5.8M | -20.62% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Context Therapeutics Inc. has no earnings call transcript available.
“Given the challenging market conditions for emerging companies, the increasingly competitive landscape for breast cancer treatments, and recent study findings, we have decided to discontinue the development of ONA-XR,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Therapeutics ® Context Therapeutics Inc. (Nasdaq: CNTX) is a biopharmaceutical company committed to advancing medicines for solid tumors. Context is developing CTIM-76, a selective Claudin 6 (CLDN6) x CD3 bispecific antibody for CLDN6-positive tumors, currently in preclinical development. Context is headquartered in Philadelphia.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Context Therapeutics Inc.’s Item 2.02 8-K filed March 22, 2023; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.